Skip to main content

Advertisement

Table 3 Incidence of solicited systemic adverse events per vaccine type per dose

From: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

   First dose Second dose Third dose
   15 μg MSP3 30 μg MSP3 Engerix B 15 μg MSP3 30 μg MSP3 Engerix B 15 μg MSP3 30 μg MSP3 Engerix B
   N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15
Symptom Intensity n % n % n % n % n % n % n % n % n %
Any Overall 6 40 6 40 5 53 1 6.7 0 0 2 13 0 0 1 6.7 0 0
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fever Overall 2 13 2 13 2 13 1 6.7 0 0 2 13 0 0 1 6.7 0 0
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Irritability Overall 2 13 0 0 2 13 0 0 0 0 0 0 0 0 0 0 0 0
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Drowsiness Overall 1 6.7 1 6.7 1 6.7 0 0 0 0 0 0 0 0 0 0 0 0
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Loss of appetite Overall 5 33 5 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0